Company Overview

Seer, Inc. is a U.S.-based life sciences company focused on proteomics, the large-scale study of proteins and their role in biological systems. The company develops technologies intended to enable researchers and biopharmaceutical companies to perform unbiased, deep, and scalable proteomic analysis. Seer primarily operates within the biotechnology tools and life sciences instrumentation industries, with a business model centered on instrument platform adoption, consumable sales, and related research collaborations. Its core offerings include the Proteograph Product Suite, which combines engineered nanoparticles, automation workflows, and software analytics designed to improve protein detection across complex biological samples.

The company was founded in 2017 and is headquartered in Redwood City, California. Seer emerged from research involving nanoparticle engineering and proteomic analysis technologies developed to address limitations in traditional mass spectrometry workflows. Since its initial public offering in 2020, the company has focused on expanding commercial adoption among academic research institutions, pharmaceutical companies, and translational medicine organizations. Seer’s strategic positioning is based on enabling broader and deeper proteomic insights at scale, particularly for biomarker discovery, precision medicine research, and systems biology applications.

Business Operations

Seer generates revenue primarily through sales of its Proteograph platforms, associated consumables, software solutions, and service-related activities. The company’s operating model emphasizes recurring consumable revenue tied to ongoing use of its nanoparticle-based proteomics workflows. Seer collaborates with mass spectrometry ecosystem providers and research institutions to integrate its technology into existing proteomics laboratories. The company’s technology stack includes engineered nanoparticle panels, sample preparation workflows, automation tools, and cloud-enabled data analysis capabilities intended to improve throughput and reproducibility.

Operations are primarily concentrated in the United States, though Seer also serves customers in Europe and parts of Asia-Pacific through direct commercial activity and distribution relationships. The company has established collaborations with pharmaceutical and biotechnology organizations pursuing biomarker discovery and disease research applications. Public disclosures reference partnerships and interoperability with major mass spectrometry and laboratory workflow providers, although specific commercial terms for some collaborations are not fully disclosed in public filings. Data regarding certain private partnership economics is inconclusive based on available public sources.

Strategic Position & Investments

Seer’s strategic direction has focused on expanding adoption of proteomics as a routine research and clinical discovery tool. The company has invested heavily in research and development to broaden the capabilities of its nanoparticle-enabled proteomics platform and increase compatibility with next-generation mass spectrometry systems. Growth initiatives include scaling commercial penetration among large biopharmaceutical companies, increasing consumables utilization, and expanding applications in translational medicine, population-scale proteomics, and multi-omics research.

The company has also pursued technology enhancement through internal development and selected collaborations rather than large-scale acquisition activity. Public filings and investor materials emphasize continued investment in automation, software analytics, and expanded workflow capabilities intended to improve scalability and reproducibility. Seer operates in an emerging segment of the proteomics market that includes increasing interest from precision medicine, drug discovery, and systems biology researchers. While the company has identified long-term opportunities in clinical and diagnostic applications, commercial deployment remains primarily research-focused based on currently available public disclosures.

Geographic Footprint

Seer is headquartered in Redwood City, California, and its primary operational footprint remains concentrated in North America. The company maintains commercial relationships with research institutions, biotechnology companies, and pharmaceutical organizations across multiple global markets. Its products are used by customers in the United States, Europe, and selected Asia-Pacific countries, reflecting growing international interest in large-scale proteomics research.

The company’s international presence is supported through direct sales efforts and distributor relationships rather than extensive overseas manufacturing infrastructure. Seer’s influence is tied primarily to adoption within global biomedical research ecosystems and collaborations with multinational pharmaceutical companies and academic research centers. Publicly available information does not indicate significant international manufacturing assets or major foreign subsidiaries as of the most recent reporting periods.

Leadership & Governance

Seer’s leadership team includes executives with backgrounds in biotechnology, genomics, diagnostics, and life sciences tools. The company was co-founded by Omid Farokhzad, whose work in nanotechnology and biomedical engineering contributed to the scientific foundation behind Seer’s platform technologies. Corporate governance is overseen by a board and executive leadership team focused on long-term platform adoption, scientific innovation, and expansion of proteomics research applications.

Key executives identified in recent public filings and company disclosures include:

• Eric Howard – Chief Executive Officer
• David Hornik – Chairperson of the Board
• Omid Farokhzad – Co-Founder and Director
• Narasimhan “Sim” Srinivasan – Chief Financial Officer
• Brian Grassadonia – President

Leadership communications in SEC filings and investor presentations emphasize scaling proteomics accessibility, advancing systems biology research, and building a recurring-revenue life sciences tools platform centered on high-throughput protein analysis technologies.